We are live on ! Find out more
DA

Dillon & Associates Portfolio holdings

AUM $726M
1-Year Est. Return 18.59%
This Fund
S&P 500
This Quarter Est. Return
+10.02%
1 Year Est. Return
+18.59%
3 Year Est. Return
+92.03%
5 Year Est. Return
+130.73%
10 Year Est. Return
+511.58%
AUM
$551M
AUM Growth
+$31.7M
Cap. Flow
-$16.8M
Cap. Flow %
-3.04%
Top 10 Hldgs %
52.81%
Holding
80
New
3
Increased
18
Reduced
52
Closed
2

Top Sells

Rank Stock Value
1
PYPL icon
PayPal
PYPL
+$3.45M
2
RTX icon
RTX Corp
RTX
+$2.99M
3
AAPL icon
Apple
AAPL
+$1.83M
4
NVDA icon
NVIDIA
NVDA
+$1.51M
5
EEFT icon
Euronet Worldwide
EEFT
+$1.1M

Sector Composition

Rank Sector Weight
1 Technology 32.97%
2 Healthcare 20.53%
3 Consumer Discretionary 12.38%
4 Communication Services 8.65%
5 Consumer Staples 7.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BDX icon
76
Becton Dickinson
BDX
$45.6B
$216K 0.04%
884
-47
-5% -$11.6K
EEFT icon
77
Euronet Worldwide
EEFT
$2.72B
$207K 0.04%
2,050
-12,876
-86% -$1.1M
HBAN icon
78
Huntington Bancshares
HBAN
$34.4B
$194K 0.04%
14,951
+270
+2% +$2.95K
BMY icon
79
Bristol-Myers Squibb
BMY
$133B
-3,715
Closed -$215K
PCRX icon
80
Pacira BioSciences
PCRX
$1.04B
-7,749
Closed -$240K

Similar funds

Dillon & Associates's Q4 2023 Portfolio in Review

As of Q4 2023, Dillon & Associates held 80 positions worth $551M, up 6.1% from $520M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Dillon & Associates withdrew a net $16.8M in Q4 2023, closing 2 positions and reducing 52 holdings. Its most notable exit was Pacira BioSciences, an estimated $240K position sold in full.

By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Dillon & Associates opened a new position in Rockwell Automation worth $2.51M.

  • Dillon & Associates's largest Q4 2023 buy was Rockwell Automation: 8,095 shares worth $2.51M.
  • Dillon & Associates added most to Paycom in Q4 2023, an estimated $2.07M increase.
  • Dillon & Associates's biggest Q4 2023 reduction was PayPal, cutting an estimated $3.45M.
  • Dillon & Associates fully exited Pacira BioSciences in Q4 2023, selling an estimated $240K.
  • Dillon & Associates's ten largest holdings make up 53% of its $551M portfolio in Q4 2023.
  • Dillon & Associates opened 3 new positions and closed 2 in Q4 2023.
  • Dillon & Associates's portfolio value rose 6.1% quarter-over-quarter to $551M.

Based on Dillon & Associates's 13F filing for Q4 2023, filed 8 Feb 2024.